Table 1 Characteristics of participants.

From: Obestatin and growth hormone reveal the interaction of central obesity and other cardiometabolic risk factors of metabolic syndrome

 

NRFNO

NRFO

RFNO

RFO

n

53

33

10

37

Female (%)

81

79

60

70

Age (years)

61.13 ± 5.35

57.72 ± 9.73

64.10 ± 4.93

63.54 ± 12.06

SBP (mmHg)

117.58 ± 7.33

120.09 ± 8.67

170.50 ± 10.6

157.95 ± 20.68

DP (mmHg)

70.26 ± 5.69

71.00 ± 6.09

82.00 ± 8.71

85.89 ± 10.08

WC (cm)

74.45 ± 5.61

86.60 ± 4.50

80.10 ± 4.46

92.73 ± 9.75

TG (mmol/L)

1.05 ± 0.30

1.06 ± 0.28

2.27 ± 0.52

2.55 ± 0.92

FBG (mmol/L)

4.96 ± 0.31

5.08 ± 0.29

6.56 ± 0.77

6.87 ± 1.36

HDL-C (mmol/L)

1.69 ± 0.35

1.65 ± 0.33

1.04 ± 0.16

0.99 ± 0.15

  1. NRFNO, group of participants with no cardiometabolic risk factors; NRFO: group of participants with central obesity but no other cardiometabolic risk factors; RFNO: group of participants with no central obesity but all other four cardiometabolic risk factors: RFO: group of participants with all cardiometabolic risk factors; SBP, systolic blood pressure; DBP, diastolic blood pressure; WC, waist circumference; TG, triglycerides; FBG, fasting blood glucose; HDL-C, high-density lipoprotein cholesterol.
Back to article page